Your browser doesn't support javascript.
loading
Peptide-based therapeutic cancer vaccine: Current trends in clinical application.
Liu, Wensi; Tang, Haichao; Li, Luanfeng; Wang, Xiangyi; Yu, Zhaojin; Li, Jianping.
Afiliação
  • Liu W; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Tang H; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Liaoning Cancer immune peptide drug Engineering Technology Research Center, Shenyang, China.
  • Li L; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Wang X; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Liaoning Cancer immune peptide drug Engineering Technology Research Center, Shenyang, China.
  • Yu Z; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Li J; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Liaoning Cancer immune peptide drug Engineering Technology Research Center, Shenyang, China.
Cell Prolif ; 54(5): e13025, 2021 May.
Article em En | MEDLINE | ID: mdl-33754407
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Vacinas Anticâncer / Neoplasias Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Cell Prolif Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Vacinas Anticâncer / Neoplasias Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Cell Prolif Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido